查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827807

2025年全球药物-器械组合市场报告

Drug Device Combination Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，药械组合市场快速扩张，规模从2024年的1,310.1亿美元成长至2025年的1,442.2亿美元，复合年增长率为10.1%。预测期内的成长可归因于医疗创新的不断增加、慢性病的增加、以患者为中心的诊疗方法、生技药品的进步、单一疗法的挑战以及临床需求。

预计未来几年，药械组合市场规模将快速成长，到2029年将达到2,246.8亿美元，复合年增长率为11.7%。预测期内的成长可归因于患者赋权和参与、医疗保健数位化、全球市场不断扩张、新型治疗方法的涌现以及基于价值的医疗保健。预测期内的主要趋势包括治疗进展、复杂疾病管理、以患者为中心的护理、技术创新以及监管支持。

药物-医疗设备组合是指将医疗设备与药物结合的治疗或诊断产品，旨在实现局部给药、精准标靶给药和个人化治疗。这些组合构成一个物理和化学上统一的实体，并被包装在一起。药物-器械组合在临床开发中发挥重要作用，能够将药物输送到体内的特定部位。

主要的药械组合产品类型包括自动注射器、微针贴片、数位药丸、智慧吸入器、药物输送水凝胶和药物释放型镜片。这些产品应用于整形外科、呼吸系统疾病、糖尿病、肿瘤科和心血管疾病等多个医疗领域。药械组合产品的最终用户包括诊所、医院、居家照护机构和门诊护理中心。这些产品透过直接竞标、零售和其他分销管道分销。

2025年春季，美国关税突然上调及其引发的贸易摩擦对医疗设备产业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要重新认证医疗设备，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准产品的国内生产以及加快研发更具成本效益的材料来降低风险。

本研究报告是商业研究公司（The Business Research Company）新报告系列的一部分，该系列提供药械组合市场统计数据，例如全球市场规模、区域份额、药械组合市场份额的竞争对手、详细的药械组合市场细分、市场趋势和商业机会，以及在药械组合行业取得成功所需的数据。本研究报告对产业现状和未来趋势进行了详细分析，提供您所需的所有资讯。

我们预测未来五年该市场将成长11.7%，较先前预测略有下降0.2%。这一下降主要源自于美国与其他国家之间关税的影响。美国可能会直接感受到这种影响，因为来自荷兰和瑞典等主要地区的药物涂层聚合物基质和组合药物包装的供应链将中断，从而导緻美国食品药物管理局(FDA)核准延迟，并增加整合疗法的开发成本。由于互惠关税以及不断升级的贸易摩擦和限制对全球经济和贸易的负面影响，这种影响也将更加广泛。

由于慢性病的盛行率不断上升，药物-医疗设备组合市场正在经历显着增长。慢性病是指持续一年以上且需要持续医疗照护的疾病，包括心臟病和糖尿病等。治疗和诊断组合在有效治疗慢性病患者方面发挥着至关重要的作用。根据世界卫生组织 (WHO) 的报告，预计到 2022 年，全球糖尿病患者人数将超过 4.2 亿，到 2030 年将增至 5.78 亿，到 2045 年将达到 7 亿。盛行率的上升凸显了药物-器械组合在慢性病管理中的关键作用，从而推动了市场的成长。

预计未来事故死亡和受伤人数的增加将推动药械联合治疗市场的成长。事故是指意外或非计划发生的事件，会导致非故意的伤害、损坏、损伤或损失，通常是由人为错误、疏忽、环境条件和机械故障等多种因素造成的。药物医疗设备组合对于管理和预防事故至关重要，因为它可以提供有针对性的医疗干预措施并提高病人安全性。例如，2024 年 5 月，加拿大政府机构加拿大运输部报告称，2022 年机动车事故死亡人数将达到 1,931 人，比总合一年的 1,821 人增加 6.0%，是过去十年中的第二高。因此，事故死亡和受伤人数的增加正在推动药械联合治疗市场的发展。

药械组合市场涵盖导管和高级创伤护理产品的销售。该市场的价值为“出厂价”，即产品製造商或生产商向其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接向最终客户销售的产品价值。该市场的产品价值还包括产品製造商提供的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球製药设备市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球药械组合市场：成长率分析
  • 全球药物-器械组合市场表现：规模与成长，2019-2024
  • 全球药械组合市场预测：2024-2029年及2034年规模与成长
  • 全球药物-器械组合：总目标市场（TAM）

第六章 市场细分

  • 全球药物-器材组合市场：依产品、实际状况及预测，2019-2024 年、2024-2029 年、2034 年
  • 自动注射器
  • 微针贴片
  • 数字药丸
  • 智慧吸入器
  • 药物输送水凝胶
  • 药物释放型镜片
  • 其他产品
  • 全球药物-器材组合市场：按分销管道、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 直接竞标
  • 零售额
  • 其他分销管道
  • 全球药械组合市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 整形外科疾病
  • 呼吸系统疾病
  • 糖尿病
  • 肿瘤学
  • 心血管疾病
  • 其他用途
  • 全球药物-器械组合市场：按最终用户、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 诊所
  • 医院
  • 居家照护环境
  • 门诊治疗中心
  • 其他最终用户
  • 全球药物-设备组合市场：依自动注射器类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 预填充自动注射器
  • 可重复使用的自动注射器
  • 全球药物-设备组合市场：按微针贴片类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 可溶性微针贴片
  • 涂层微针贴片
  • 全球药械组合市场：按数字药丸细分，类型，实际和预测，2019-2024 年，2024-2029 年，2034 年
  • 可摄入感测器
  • 智慧胶囊
  • 全球药物-设备组合市场：智慧吸入器的细分（按类型）、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 定量喷雾吸入器（MDI）
  • 干粉吸入器（DPI）
  • 全球药物-器械组合市场：按药物输送水凝胶（按类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 可注射水凝胶
  • 外用水凝胶
  • 全球药物-器械组合市场：药物释放型镜片细分（按类型）、实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 隐形眼镜
  • 人工水晶体
  • 全球药物-器材组合市场：依产品类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 经皮吸收贴片
  • 植入式药物传输系统

第七章 区域和国家分析

  • 全球药物-器材组合市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球药物-器械组合市场：按国家、实际结果和预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 药物-器材组合市场：竞争格局
  • 药物-器械组合市场：公司简介
    • The 3M Company Overview, Products and Services, Strategy and Financial Analysis
    • Abbott India Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Biotronik SE & Co. KG Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic PLC Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Ypsomed Holding AG
  • Micron Biomedical Inc.
  • MetP Pharma AG
  • Sonceboz SA
  • Lepu Medical Technology（Beijing）Co. Ltd.
  • Eitan Medical Ltd.
  • Vaxess Technologies Inc.
  • Subcuject Aps
  • Allergan PLC
  • Terumo Corporation
  • Stryker Corporation
  • Becton Dickinson and Company
  • Zimmer Biomet Holdings Inc.
  • MediPrint Ophthalmics
  • Arrow International Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年药械组合市场：提供新机会的国家
  • 2029年药械组合市场：细分领域带来新机会
  • 2029年药械组合市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r22555u

Drug-device combinations refer to therapeutic and diagnostic products that combine a medical device with a drug, facilitating localized drug administration, precise drug targeting, and personalized therapy. These combinations create a unified entity, physically and chemically, packaged together in a single package. Drug-device combinations play a crucial role in clinical development, enabling the delivery of drugs to specific locations in the body.

The primary types of drug-device combination products include auto-injectors, microneedle patches, digital pills, smart inhalers, drug delivery hydrogels, drug-eluting lenses, and other products. These products find applications in various medical fields such as orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, among others. The end users of drug-device combination products include clinics, hospitals, home care settings, ambulatory care centers, and others. These products are distributed through direct tenders, retail sales, and other distribution channels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The drug-device combination market research report is one of a series of new reports from The Business Research Company that provides drug-device combination market statistics, including drug-device combination industry global market size, regional shares, competitors with an drug-device combination market share, detailed drug-device combination market segments, market trends and opportunities, and any further data you may need to thrive in the drug-device combination industry. This drug-device combination market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug device combination market size has grown rapidly in recent years. It will grow from $131.01 billion in 2024 to $144.22 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing medical innovation, rise in chronic diseases, patient-centric approaches, advances in biologics, challenges of monotherapy, clinical needs.

The drug device combination market size is expected to see rapid growth in the next few years. It will grow to $224.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to patient empowerment and engagement, healthcare digitalization, global market expansion, emergence of novel therapies, value-based healthcare. Major trends in the forecast period include therapeutic advancements, complex disease management, patient-centric care, technological innovations, and regulatory support.

The forecast of 11.7% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for drug-coated polymer matrices and combination product packaging, sourced from key regions such as the Netherlands and Sweden, which could lead to delayed Food and Drug Administration (FDA) approvals and increased development costs for integrated therapies.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The drug-device combination market is witnessing substantial growth driven by the increasing prevalence of chronic diseases. Chronic diseases, persisting for a year or longer and requiring ongoing medical care, include conditions like heart disease and diabetes. Drug-device combinations, encompassing therapeutic and diagnostic products, play a pivotal role in effectively treating individuals with chronic diseases. As per the World Health Organization's report, the global incidence of diabetes surpassed 420 million in 2022, with projections indicating a rise to 578 million by 2030 and 700 million by 2045. This escalating prevalence underscores the critical role of drug-device combinations in managing chronic diseases, thereby propelling the growth of the market.

An increase in casualties due to accidents is anticipated to drive the growth of the drug-device combination market in the future. Accidents refer to unexpected events or unplanned incidents that result in unintended harm, damage, injury, or loss, often arising from a mix of factors such as human error, negligence, environmental conditions, or mechanical failure. Drug-device combinations are essential in managing and preventing accidents by providing targeted medical interventions and improving patient safety. For example, in May 2024, Transport Canada, a government agency in Canada, reported that motor vehicle fatalities reached 1,931 in 2022, representing a 6.0% increase from the previous year's total of 1,821, and marking the second highest figure recorded in the past decade. Consequently, the rise in casualties resulting from accidents is fueling the drug-device combination market.

Major companies in the drug combination device market are developing innovative products like Trelegy Ellipta to maintain their market position. Trelegy Ellipta is an inhaler designed to deliver a specific dosage of medication directly to the lungs and is recognized as the first single-inhaler triple therapy. For example, in April 2022, GSK, a UK-based pharmaceutical and biotechnology company, introduced Trelegy Ellipta. This inhaler is a compact and portable device used to treat chronic obstructive pulmonary disease (COPD) and asthma. Ellipta inhalers can accommodate up to three different types of drugs in foil packaging for combination therapy. Trelegy Ellipta is a drug combination device that features three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. It enhances patient management of respiratory conditions through its integrated delivery system.

Major companies in the drug-device combination market are introducing innovative products such as the G-Lasta Subcutaneous Injection 3.6 mg BodyPod to simplify the administration process. The G-Lasta Subcutaneous Injection 3.6 mg BodyPod is a drug-device combination that includes an automated injection device and G-Lasta (pegfilgrastim), a medication given to patients undergoing chemotherapy to reduce the occurrence of febrile neutropenia. For instance, in December 2022, Terumo Corporation, a Japan-based medical device company, collaborated with Kyowa Kirin, a Japan-based pharmaceutical company, to launch the G-Lasta Subcutaneous Injection 3.6 mg BodyPod. G-Lasta is utilized during chemotherapy to decrease the incidence of febrile neutropenia. The automated injection device is connected at the hospital on the day of chemotherapy and automatically administers the drug approximately 27 hours later. This feature eliminates the need for an extra outpatient visit, thereby easing the burden on patients.

In May 2023, Closed Loop Medicine Ltd, a UK-based TechBio company focused on developing combination prescription drug and software therapy products, formed a partnership with Pharmanovia. Through this collaboration, Closed Loop Medicine Ltd. aims to advance precision medicine strategies that utilize genetic and molecular profiling to determine the most effective drug combinations for individual patients. Pharmanovia is a pharmaceutical company based in the UK.

Major companies operating in the drug device combination market are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic PLC, Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan PLC, Terumo Corporation, Stryker Corporation, Becton Dickinson and Company, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc.

North America was the largest region in the drug-device combination market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug device combination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug-device combination market consists of sales of catheter and advanced wound care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Device Combination Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug device combination market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug device combination ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug device combination market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Auto-Injector; Microneedle Patch; Digital Pill; Smart Inhaler; Drug Delivery Hydrogels; Drug-Eluting Lens; Other Products
  • 2) By Distribution Channel: Direct Tender; Retails Sales; Other Distribution Channels
  • 3) By Application: Orthopedic Diseases; Respiratory Diseases; Diabetes; Oncology; Cardiovascular Diseases; Other Applications
  • 4) By End User: Clinics; Hospitals; Home Care Settings; Ambulatory Care Centers; Other End Users
  • Subsegments:
  • 1) By Auto-Injector: Pre-Filled Auto-Injectors; Reusable Auto-Injectors
  • 2) By Microneedle Patch: Dissolving Microneedle Patches; Coated Microneedle Patches
  • 3) By Digital Pill: Ingestible Sensors; Smart Capsules
  • 4) By Smart Inhaler: Metered-Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs)
  • 5) By Drug Delivery Hydrogels: Injectable Hydrogels; Topical Hydrogels
  • 6) By Drug-Eluting Lens: Contact Lenses; Intraocular Lenses
  • 7) By Other Products: Transdermal Patches; Implantable Drug Delivery Systems
  • Companies Mentioned: The 3M Company; Abbott India Ltd.; Biotronik SE & Co. KG; Boston Scientific Corporation; Medtronic PLC; Ypsomed Holding AG; Micron Biomedical Inc.; MetP Pharma AG; Sonceboz SA; Lepu Medical Technology (Beijing) Co. Ltd.; Eitan Medical Ltd.; Vaxess Technologies Inc.; Subcuject Aps; Allergan PLC; Terumo Corporation; Stryker Corporation; Becton Dickinson and Company; Zimmer Biomet Holdings Inc.; MediPrint Ophthalmics; Arrow International Inc.; Alcon Inc.; W. L. Gore & Associates Inc.; Cook Medical LLC; Pinnacle Biologics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drug Device Combination Market Characteristics

3. Drug Device Combination Market Trends And Strategies

4. Drug Device Combination Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Drug Device Combination Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Drug Device Combination PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Drug Device Combination Market Growth Rate Analysis
  • 5.4. Global Drug Device Combination Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Drug Device Combination Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Drug Device Combination Total Addressable Market (TAM)

6. Drug Device Combination Market Segmentation

  • 6.1. Global Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Auto-Injector
  • Microneedle Patch
  • Digital Pill
  • Smart Inhaler
  • Drug Delivery Hydrogels
  • Drug-Eluting Lens
  • Other Products
  • 6.2. Global Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Direct Tender
  • Retails Sales
  • Other Distribution Channels
  • 6.3. Global Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Orthopedic Diseases
  • Respiratory Diseases
  • Diabetes
  • Oncology
  • Cardiovascular Diseases
  • Other Applications
  • 6.4. Global Drug Device Combination Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinics
  • Hospitals
  • Home Care Settings
  • Ambulatory Care Centers
  • Other End Users
  • 6.5. Global Drug Device Combination Market, Sub-Segmentation Of Auto-Injector, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pre-Filled Auto-Injectors
  • Reusable Auto-Injectors
  • 6.6. Global Drug Device Combination Market, Sub-Segmentation Of Microneedle Patch, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dissolving Microneedle Patches
  • Coated Microneedle Patches
  • 6.7. Global Drug Device Combination Market, Sub-Segmentation Of Digital Pill, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ingestible Sensors
  • Smart Capsules
  • 6.8. Global Drug Device Combination Market, Sub-Segmentation Of Smart Inhaler, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metered-Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • 6.9. Global Drug Device Combination Market, Sub-Segmentation Of Drug Delivery Hydrogels, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Injectable Hydrogels
  • Topical Hydrogels
  • 6.10. Global Drug Device Combination Market, Sub-Segmentation Of Drug-Eluting Lens, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Contact Lenses
  • Intraocular Lenses
  • 6.11. Global Drug Device Combination Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transdermal Patches
  • Implantable Drug Delivery Systems

7. Drug Device Combination Market Regional And Country Analysis

  • 7.1. Global Drug Device Combination Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Drug Device Combination Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drug Device Combination Market

  • 8.1. Asia-Pacific Drug Device Combination Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drug Device Combination Market

  • 9.1. China Drug Device Combination Market Overview
  • 9.2. China Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drug Device Combination Market

  • 10.1. India Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drug Device Combination Market

  • 11.1. Japan Drug Device Combination Market Overview
  • 11.2. Japan Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drug Device Combination Market

  • 12.1. Australia Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drug Device Combination Market

  • 13.1. Indonesia Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drug Device Combination Market

  • 14.1. South Korea Drug Device Combination Market Overview
  • 14.2. South Korea Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drug Device Combination Market

  • 15.1. Western Europe Drug Device Combination Market Overview
  • 15.2. Western Europe Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drug Device Combination Market

  • 16.1. UK Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drug Device Combination Market

  • 17.1. Germany Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drug Device Combination Market

  • 18.1. France Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drug Device Combination Market

  • 19.1. Italy Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drug Device Combination Market

  • 20.1. Spain Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drug Device Combination Market

  • 21.1. Eastern Europe Drug Device Combination Market Overview
  • 21.2. Eastern Europe Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drug Device Combination Market

  • 22.1. Russia Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drug Device Combination Market

  • 23.1. North America Drug Device Combination Market Overview
  • 23.2. North America Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drug Device Combination Market

  • 24.1. USA Drug Device Combination Market Overview
  • 24.2. USA Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drug Device Combination Market

  • 25.1. Canada Drug Device Combination Market Overview
  • 25.2. Canada Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drug Device Combination Market

  • 26.1. South America Drug Device Combination Market Overview
  • 26.2. South America Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drug Device Combination Market

  • 27.1. Brazil Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drug Device Combination Market

  • 28.1. Middle East Drug Device Combination Market Overview
  • 28.2. Middle East Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drug Device Combination Market

  • 29.1. Africa Drug Device Combination Market Overview
  • 29.2. Africa Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drug Device Combination Market Competitive Landscape And Company Profiles

  • 30.1. Drug Device Combination Market Competitive Landscape
  • 30.2. Drug Device Combination Market Company Profiles
    • 30.2.1. The 3M Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbott India Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Biotronik SE & Co. KG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Medtronic PLC Overview, Products and Services, Strategy and Financial Analysis

31. Drug Device Combination Market Other Major And Innovative Companies

  • 31.1. Ypsomed Holding AG
  • 31.2. Micron Biomedical Inc.
  • 31.3. MetP Pharma AG
  • 31.4. Sonceboz SA
  • 31.5. Lepu Medical Technology (Beijing) Co. Ltd.
  • 31.6. Eitan Medical Ltd.
  • 31.7. Vaxess Technologies Inc.
  • 31.8. Subcuject Aps
  • 31.9. Allergan PLC
  • 31.10. Terumo Corporation
  • 31.11. Stryker Corporation
  • 31.12. Becton Dickinson and Company
  • 31.13. Zimmer Biomet Holdings Inc.
  • 31.14. MediPrint Ophthalmics
  • 31.15. Arrow International Inc.

32. Global Drug Device Combination Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Device Combination Market

34. Recent Developments In The Drug Device Combination Market

35. Drug Device Combination Market High Potential Countries, Segments and Strategies

  • 35.1 Drug Device Combination Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Drug Device Combination Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Drug Device Combination Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer